Illumina/$ILMN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Illumina
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Ticker
$ILMN
Sector
Primary listing
Employees
9,000
Headquarters
Website
Illumina Metrics
BasicAdvanced
$16B
12.76
$7.91
1.43
-
Price and volume
Market cap
$16B
Beta
1.43
52-week high
$156.66
52-week low
$68.70
Average daily volume
1.5M
Financial strength
Current ratio
1.808
Quick ratio
1.281
Long term debt to equity
89.46
Total debt to equity
115.058
Interest coverage (TTM)
7.73%
Profitability
EBITDA (TTM)
1,065.7
Gross margin (TTM)
68.16%
Net profit margin (TTM)
29.34%
Operating margin (TTM)
18.04%
Effective tax rate (TTM)
9.89%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
7.94%
Return on equity (TTM)
68.06%
Valuation
Price to earnings (TTM)
12.758
Price to revenue (TTM)
3.734
Price to book
6.88
Price to tangible book (TTM)
17.14
Price to free cash flow (TTM)
15.515
Free cash flow yield (TTM)
6.45%
Free cash flow per share (TTM)
6.505
Growth
Revenue change (TTM)
-3.27%
Earnings per share change (TTM)
-141.19%
3-year revenue growth (CAGR)
-2.99%
10-year revenue growth (CAGR)
7.54%
3-year earnings per share growth (CAGR)
294.73%
10-year earnings per share growth (CAGR)
9.22%
What the Analysts think about Illumina
Analyst ratings (Buy, Hold, Sell) for Illumina stock.
Bulls say / Bears say
Illumina beat Q2 2025 estimates, posting $1.06 billion in revenue versus the $1.05 billion consensus and adjusted EPS of $1.19, well above the $1.01 forecast; non-GAAP operating margin climbed to 23.8%, and management raised full-year EPS guidance to $4.45–$4.55 (Reuters)
Illumina ranked fifth on TIME’s World’s Most Sustainable Companies list in 2024, underscoring its ESG leadership and innovations like a 90% cut in packaging for MiSeq i100 Series sequencers (TIME)
The June 2025 acquisition agreement for SomaLogic at $350 million (plus up to $75 million in milestones) accelerates Illumina’s multiomics push by adding proteomics expertise to its NGS platforms, creating a new high-margin revenue stream (PRNewswire)
Illumina’s 2025 revenue guidance was cut to $4.28 billion–$4.40 billion, below Wall Street’s consensus of $4.39 billion, reflecting weaker than expected demand for sequencing products amid industry funding constraints (Reuters)
China’s ban on imports of Illumina’s sequencing systems—which made up about 7% of 2024 revenue—resulted in narrowed 2025 non-GAAP EPS guidance of approximately $4.50 and a $100 million cost-reduction initiative to offset the lost sales (Reuters)
Political risks and rising competition are dampening Illumina’s growth. U.S. trade policies have led China to deem the company “unreliable” and NIH funding is capped, while Roche’s launch of a new sequencing platform intensifies pressure on Illumina’s market share (WSJ)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Illumina Financial Performance
Revenues and expenses
Illumina Earnings Performance
Company profitability
Illumina News
AllArticlesVideos
BioStem Technologies Appoints Brandon Poe as Chief Financial Officer
MCAP MediaWire1 month ago
These Analysts Boost Their Forecasts On Illumina Following Upbeat Results
Benzinga2 months ago
Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Illumina stock?
Illumina (ILMN) has a market cap of $16B as of September 16, 2025.
What is the P/E ratio for Illumina stock?
The price to earnings (P/E) ratio for Illumina (ILMN) stock is 12.76 as of September 16, 2025.
Does Illumina stock pay dividends?
No, Illumina (ILMN) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Illumina dividend payment date?
Illumina (ILMN) stock does not pay dividends to its shareholders.
What is the beta indicator for Illumina?
Illumina (ILMN) has a beta rating of 1.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.